Product Images Tiagabine Hydrochloride
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 13 images provide visual information about the product associated with Tiagabine Hydrochloride NDC 0093-8072 by Teva Pharmaceuticals Usa, Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
structure - tiagabine hcl tablets 2 mg 4 mg 12 mg 16 mg 1
Tiagabine Hydrochloride Tablets 2 mg, 30s Label - tiagabine hcl tablets 2 mg 4 mg 12 mg 16 mg 10
This appears to be a medication label for Tiagabine Hydrochloride tablets, including dosage instructions and the name of the manufacturer (Teva). It also indicates that a medication guide is required and provides a code number for the product.*
Tiagabine Hydrochloride Tablets 4 mg, 30s Label - tiagabine hcl tablets 2 mg 4 mg 12 mg 16 mg 11
Tiagabine Hydrochloride Tablets 12 mg, 30s Label - tiagabine hcl tablets 2 mg 4 mg 12 mg 16 mg 12
Tiagabine Hydrochloride Tablets 16 mg, 30s Label - tiagabine hcl tablets 2 mg 4 mg 12 mg 16 mg 13
figure01 - tiagabine hcl tablets 2 mg 4 mg 12 mg 16 mg 2
This text appears to be a graph depicting the % reduction in partial seizure rate for patients taking Tiagabine HCI 32 + 55 mg/day compared to a placebo. The graph shows a 50% reduction in seizure rate for patients taking Tiagabine, while the placebo group shows no improvement in seizure rate. The graph also includes a scale ranging from -50% to 50%, indicating the degree of improvement or worsening in seizure rate. It appears to be a medical or pharmaceutical study, but without further context, it is difficult to provide a more specific description.*
figure02 - tiagabine hcl tablets 2 mg 4 mg 12 mg 16 mg 3
The text appears to be a chart showing the % reduction in partial seizure rate for patients with different dosages of Tiagabine HCI and a placebo. The chart also shows the % of patients who experienced improvement, no change, or worsening of symptoms.*
figure03 - tiagabine hcl tablets 2 mg 4 mg 12 mg 16 mg 4
The text is a chart that shows the percentage reduction in partial seizure rate for patients taking a placebo versus patients taking Tiagabine HCI at different doses. It also provides the percentage of patients who experienced improvement in seizure rate or no change/worsening.*
figure04 - tiagabine hcl tablets 2 mg 4 mg 12 mg 16 mg 5
The text presents a graph that shows the reduction in partial seizure rate for patients taking a placebo and those taking Tiagabine HCI 10 mg TID. The graph indicates that the reduction in partial seizure rate is 100% for those taking Tiagabine HCI. Therefore, Tiagabine HCI can be considered an effective treatment for partial seizures.*
figure05 - tiagabine hcl tablets 2 mg 4 mg 12 mg 16 mg 6
figure06 - tiagabine hcl tablets 2 mg 4 mg 12 mg 16 mg 7
image07 - tiagabine hcl tablets 2 mg 4 mg 12 mg 16 mg 8
image08 - tiagabine hcl tablets 2 mg 4 mg 12 mg 16 mg 9
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.